MetaCap

Moleculin Biotech (MBRX) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quantum Biopharma is the larger company by market cap ($8.3 million vs $8.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBRX+1663.50%QNTM-58.98%
+2114%+976%-162%
Oct 7, 20261 yearNov 20, 2026
MBRX+1651.13%QNTM-56.12%
+1965%+906%-152%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBRX versus QNTM key metrics
MetricMBRXQNTM
Share price$7.74$1.29
Market cap$8.22M$8.29M
1-day change-2.40%-9.15%
YTD return—-82.33%
1-year return—-77.60%
5-year return—-98.51%
P/E ratio (TTM)0.04—
EPS (TTM)$179.60$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-33.56M—
52-week high$202.50$12.42
52-week low$3.22$1.26
Distance from 52-week high-96.18%-89.61%
Analyst consensusstrong_buynone
Avg. price target upside+55.04%+851.16%
Average volume44.66K148.83K
Shares outstanding1.06M6.43M
Employees17—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

MBRX vs QNTM FAQ

Which is bigger, Moleculin Biotech or Quantum Biopharma?

Quantum Biopharma (QNTM) is larger, with a market capitalization of $8.29M compared with $8.22M for Moleculin Biotech (MBRX).

Are Moleculin Biotech and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons